June 7, 2017 / 11:33 AM / in 6 months

BRIEF-Trillium expands clinical trial with TTI-621

June 7 (Reuters) - Trillium Therapeutics Inc

* Trillium expands clinical trial with tti-621 to include combination with pd-1 blockade

* Trillium therapeutics inc - ‍further expanded its current intravenous dosing trial of tti-621, an igg1 sirpafc fusion protein targeting cd47​

* Trillium therapeutics inc - ‍changes to trial include increasing size of cohorts exhibiting early evidence of clinical benefit, among others​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below